Hypothesis

Pulsed low‑dose IGF‑1 administered together with BPC‑157 and TB‑500 will accelerate tendon fibroblast migration and extracellular matrix deposition in human tendons more effectively than any single peptide, while keeping mTOR‑driven proliferative signaling below a threshold associated with increased oncogenic risk.

Mechanistic Rationale

• BPC‑157 up‑regulates growth hormone receptor (GHR) expression in tendon fibroblasts, priming JAK2‑STAT5 signaling [2].
• TB‑500, a thymosin β4 fragment, sequesters G‑actin and promotes actin‑polymerization cycles that enhance lamellipodia formation and focal adhesion kinase (FAK) activation [4].
• IGF‑1 binds IGF‑1R, triggering a transient PI3K‑Akt‑mTOR burst that stimulates protein synthesis; however, continuous activation drives pathological growth [6]. We propose that the GHR‑JAK2 priming by BPC‑157 lowers the IGF‑1 concentration needed for downstream Akt phosphorylation, allowing a short IGF‑1 pulse to achieve sufficient mTORC1 activity for collagen synthesis without sustaining the signal. Simultaneously, TB‑500‑mediated actin remodeling positions fibroblasts at the injury site, where FAK‑Src complexes amplify JAK‑STAT signaling, creating a positive feedback loop that drives migration and matrix deposition. The intermittent nature of IGF‑1 exposure limits mTORC1 duration, reducing the chance of uncontrolled proliferation that could raise tumorigenic potential.

Experimental Design

A double‑blind, placebo‑controlled pilot trial enrolling 30 participants with acute mid‑substance Achilles tendinopathy confirmed by ultrasound. Participants are randomized (1:1:1:1) to four groups for 4 weeks:

1. Placebo saline injections.
2. BPC‑157 2 mg + TB‑500 2 mg subcutaneously, twice weekly.
3. IGF‑1 LR3 0.05 mg kg⁻¹ subcutaneously, pulsed (three 5‑minute infusions per week).
4. Combination: BPC‑157 2 mg + TB‑500 2 mg + IGF‑1 LR3 0.05 mg kg⁻¹ on the same schedule as groups 2 and 3. Primary endpoint: change in tendon cross‑sectional area and neovascularization on contrast‑enhanced MRI at baseline and week 4. Secondary endpoints: serum PIIINP and TIMP‑1 biomarkers, VISA‑A score, and adverse event monitoring with particular attention to IGF‑1‑related hyperplasia (e.g., prostate‑specific antigen, IGF‑1 levels).

Predicted Outcomes

If the hypothesis holds, the combination group will show a ≥25 % greater reduction in tendon area and a ≥20 % increase in neovascularization compared with the best single‑peptide group, while serum IGF‑1 remains within physiological range and no significant rise in proliferation markers (Ki‑67 in circulating mononuclear cells) is observed. Conversely, failure to demonstrate superiority or detection of mTOR‑dependent hyperproliferation would falsify the proposed synergistic mechanism.

Potential Confounds

Variability in baseline tendon load, differences in injection technique, and individual IGF‑1 sensitivity could obscure effects. Stratifying by baseline VISA‑A and monitoring compliance with loading protocols will mitigate these issues. Long‑term safety beyond four weeks remains unknown and warrants separate follow‑up.